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Available online 27 November 2015AbstractObjective: This study primarily evaluated serum 25-hydroxy vitamin D levels in postmenopausal women with vitamin D insufficiency who
received different dosages and intervals of vitamin D2 supplementation. We secondarily evaluated the percentages of those who achieved vitamin
D sufficiency level (Defined as 30 ng/ml).
Study design: Randomized double-blind, placebo-controlled trial.
Methods: Postmenopausal women who met the criteria of vitamin D insufficiency (<30 ng/mL) were randomized into 4 groups (N ¼ 25/group).
Participants received a 12 week-treatment of different dosages and intervals of vitamin D2 (placebo, vitamin D2 20,000 IU/2 weeks, vitamin D2
20,000 IU/week, and vitamin D2 40,000 IU/week). Serum total 25-hydroxy vitamin D was determined at baseline, after 4 and 12 weeks of
supplementation with electrochemiluminescence immunoassay (Elecys, Roche Diagnostics). Changes of 25-hydroxy vitamin D levels were
compared among the groups.
Results: Forty seven percent of postmenopausal women (100/212) screened for study enrolment were found to have vitamin D insufficiency. At
12 weeks, serum 25-hydroxy vitamin D increased significantly from baseline in all groups ( p < 0.01) (mean serum 25-hydroxy vitamin D level
increased from 23.03 ± 4.56 at baseline to 25.60 ± 4.79 ng/ml (placebo), 23.54 ± 5.14 to 27.83 ± 5.27 ng/ml (vitamin D2 20,000 IU/2 weeks),
22.68 ± 5.21 to 30.50 ± 5.14 ng/ml (vitamin D2 20,000 IU/week), and 22.88 ± 4.83 to 37.89 ± 5.47 ng/ml (vitamin D2 40,000 IU/week)). In
addition, the 25-hydroxy vitamin D levels were statistically significantly different at 4 and 12 weeks ( p < 0.01) among all 4 groups. The
percentages of those achieving vitamin D sufficiency level after 12 weeks of supplementation were 16% (placebo), 27.3% (vitamin D2
20,000 IU/2 weeks), 44% (vitamin D2 20,000 IU/week), and 86.4% (vitamin D2 40,000 IU/week); statistically significantly different among the
four groups ( p < 0.01). There was no participant with 25-hydroxy vitamin D after 12 weeks of >50 ng/mL in this study.
Conclusion: Vitamin D2 40,000 IU/week was found to be the most effective dosage for postmenopausal women in this study to achieve serum
vitamin D sufficiency level.
© 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Postmenopause; Vitamin D2; Ergocalciferol; Vitamin D insufficiency; Serum total 25-hydroxy vitamin D* Corresponding author.
E-mail address: worawisit@gmail.com (W. Woranitat).
Peer review under responsibility of The Korean Society of Osteoporosis.
http://dx.doi.org/10.1016/j.afos.2015.10.002
2405-5255/© 2015 The Korean Society of Osteoporosis. Production and hosting by
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is well known that adequate levels of circulating 25-
hydroxy vitamin D are important for optimal bone health. In
addition, recent observational studies appear to suggest a role
for vitamin D in the prevention of chronic diseases such as
type I diabetes, cardiovascular disease, cancer, cognitiveElsevier B.V. This is an open access article under the CC BY-NC-ND license
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international epidemiological investigation on the prevalence
of vitamin D inadequacy amongst postmenopausal women
with osteoporosis revealed that low levels of serum 25-
hydroxy vitamin D were common [5]. Women with 25-
hydroxy vitamin D level < 30 ng/mL ranged from 53.4% in
Latin American, 57.7% in Europe, 60.3% in Australia, 71.4%
in Asia and 81.8% in Middle East region. In Thailand, the
prevalence of vitamin D insufficiency (25-hydroxy vitamin D
level < 30 ng/mL) was 47% whilst the prevalence of vitamin
D deficiency (<20 ng/mL) was 12% [5].
With increasing urbanization, people tend to have more
indoor activities, minimal exposure to sunlight due to factory
and office lifestyles instead of subsistence farming. As a
consequence, people tend to have limited photochemical
subcutaneous synthesis of vitamin D. In order to prevent
inadequate levels of vitamin D, people need to increase sun-
light exposure, take a diet that includes rich sources of vitamin
D and/or take vitamin D supplementation [6,7]. Nevertheless,
to increase dietary intake to obtain adequate vitamin D is
cumbersome and difficult to achieve, while increasing expo-
sure to sunlight may not be acceptable to women due to
concerns of photo-degeneration and skin cancer. This is not to
mention the increasing use of sunscreen and umbrellas to
avoid the heat from sunlight in women from this region.
Vitamin D supplementation is deemed to be an easy and
practical solution particularly if the cost is low. As a general
guide, the recommendation is 600e800 IU vitamin D3 daily
[8], for all healthy postmenopausal women. In Thailand, a
cheap and easily available form of vitamin D is the once
weekly 20,000 IU of Vitamin D2 which costs less than 0.04
US$/week. Therefore, the primary aim of this study was to
evaluate the efficacy of different vitamin D supplementation
regimens on the serum 25-hydroxy vitamin D level in post-
menopausal women with vitamin D insufficiency. We
secondarily evaluated the percentages of those who achieved
vitamin D sufficiency level (30 ng/mL) in these different
intervention groups.
2. Methodology2.1. Study populationThis study was approved by the Research Ethics Commit-
tee of the Faculty of Medicine, Chulalongkorn University on
IRB No. 593/56, Bangkok, Thailand. All subjects provided
their written informed consent before recruitment. The study
was conducted from March 2014 to February 2015. Pilot study
was done to find an appropriate sample size which yielded 25/
group (total number ¼ 100) (a ¼ 0.05 two-sides, b ¼ 0.2).
One hundred postmenopausal women were recruited from the
menopause clinic, King Chulalongkorn Memorial Hospital.
The following were the inclusion criteria: 1) age: 50e80 years,
2) amenorrhoea for at least 12 months, 3) being ambulatory
and community-dwelling, 4) body mass index (BMI) between
18.50 and 25.00 (kg/m2), 5) baseline serum 25-hydroxy
vitamin D < 30 ng/mL and, 6) willing to give informedconsent to participate in the study. Exclusion criteria included
those with a history of liver disease or abnormal liver function
test, renal disease or abnormal renal function test, a history of
malignancy, endocrine disorders, malabsorption or bowel
surgery, or use of any vitamin D containing medications
within 12 weeks.2.2. Study designThis study is double-blind randomization design. Par-
ticipants were divided to 4 groups by “Block-of-four
randomization”. The first group was assigned to receive
two identical placebo pill once weekly. The second group
was assigned to take a) vitamin D2 (ergocalciferol)
20,000 IU and an identical placebo pill once a week and
b) two identical placebo pills once a week on an alternate
basis. The third group took one vitamin D2 (ergo-
calciferol) 20,000 IU and one placebo pill once weekly,
the fourth group took two vitamin D2 (ergocalciferol)
20,000 IU (a total dose of 40,000 IU) once weekly. The
pill, manufactured by The British Pensary (L.P) Co., Ltd.,
is a white, colourless crystal, insoluble in water, soluble in
organic solvents and slightly soluble in vegetable oils.
Serum 25-hydroxy vitamin D levels were measured at
baseline, 4 and 12 weeks after the supplementation
(Fig. 1).2.3. Vitamin D assaySerum 25-hydroxy vitamin D level was measured using an
automated Elecsys (Roche diagnostic) [9], which is an auto-
mated assay and measures total 25 hydroxy vitamin D
(D2 þ D3). Intra-assay coefficient of variability is 3.57 and
inter-assay coefficient of variability is 4.89.2.4. Statistical analysisSPSS version 17 was used for statistical analysis. Baseline
demographic data were presented as mean and standard de-
viation for continuous data and percentage for discrete data.
Comparison among groups was done using ANOVA for
continuous data and Chi square for binary or nominal data.
Comparison of the changes of serum 25-hydroxy vitamin D
after enrolment at 4 and 12 weeks of study was done using
ANCOVA. A p-value of less than 0.05 was considered statis-
tically significant.
3. Results
Forty seven percent of postmenopausal women screened for
study enrolment (100/212) had serum 25-hydroxy vitamin D
level below sufficiency level (<30 ng/mL). Ninety seven out of
100 participants completed the 12 week study. Two partici-
pants in vitamin D2 (ergocalciferol) 40,000 IU/week (one had
urticarial rash, and one relocated to another city) and one
participant in the placebo group (had urticarial rash) dropped
out of the study. The demographic data revealed no
Fig. 1. Trial flowchart summarizing the recruitment and randomization process.
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groups (Table 1).
The mean (SD) of serum 25-hydroxy vitamin D at base-
line, 4 and 12 weeks of the four groups are shown in Fig. 2.
Serum 25-hydroxy vitamin D levels increased significantly
from baseline in all groups at 4 and 12 weeks ( p < 0.01)
except the placebo group which showed no significant in-
crease in serum 25-hydroxy vitamin D level at 4 week
( p ¼ 0.10). There were statistically significant differences in
serum 25-hydroxy vitamin D levels among all four groups at 4
and 12 weeks (ANCOVA). Post hoc analysis of serum 25-
hydroxy vitamin D levels at 12 weeks (Table 2) showed that
there were statistically significant differences in the serum 25-
hydroxy vitamin D levels in almost every pair of comparisons
except between the placebo and vitamin D2 20,000 IU/
2 weeks ( p ¼ 0.13).
The percentages of participants in each group with serum
25-hydroxy vitamin D  30 ng/mL, after 12 weeks were 16%
in placebo, 27.3% in the vitamin D2 20,000 IU/2 weeks, 44%
in the vitamin D2 20,000 IU/week and 86.4% in the vitamin D2
40,000 IU/week ( p < 0.01) (Fig. 3). There was no statistically
significant difference in lifestyle i.e., exercise, sunlight expo-
sure and intake of vitamin D rich diet after 12 weeks (Table 3).
No increase in serum 25-hydroxy vitamin D of >50 ng/mL
was found in this study.4. Discussion
This study revealed that a sizable percentage (47%) of the
study population had vitamin D insufficiency when using a
cutoff value of 30 ng/mL to define level of sufficiency [8].
The percentage is exactly the same as the number reported in
2006 by Lipps P., et al. in an international epidemiology
investigation of the prevalence of vitamin D inadequacy
worldwide though the latter investigated older postmenopausal
women with osteoporosis [5]. This is in contrast to a Thai
report by Soontrapa S. et al. who found a higher percentage
(77%) of hypovitaminosis D in older women [10]. This may
be due to the higher cutoff value (>35 ng/mL) used in the
latter study compared to ours which adopted the international
cutoff value of <30 ng/mL as insufficiency.
From this study, it is found that the once weekly regimen of
vitamin D2 40,000 IU was the most effective regimen to in-
crease 25-hydroxy vitamin D to achieve sufficiency level at
12 weeks (86.4% of the participants in the group). None of the
women in this study had 25-hydroxy vitamin D level >50 ng/
mL. The once weekly dose of vitamin D2 20,000 IU is another
good option that raised 25-hydroxy vitamin D level in 44% of
participants to sufficiency levels. The results of this study are
comparable to Joseph P. et al. [11] who conducted a study
using a once weekly vitamin D2 50,000e100,000 IU which
Table 1
Baseline demographic and clinical characteristics of the studied population (N ¼ 100) by randomization.
Placebo Vitamin D2
20,000 IU/2 weeks
Vitamin D2
20,000 IU/week
Vitamin D2
40,000 IU/week
p-Value
Age (y) 60.40 (7.55) 60.50 (7.18) 62.08 (6.70) 61.52 (6.75) 0.81
BMI (kg/m2) 22.52 (1.66) 22.41 (1.84) 23.16 (1.60) 22.25 (1.69) 0.26
Age of menopause (y) 48.76 (4.03) 48.70 (4.53) 48.33 (3.96) 50.08 (2.98) 0.42
Baseline 25-hydroxy vitamin D (ng/mL) 23.03 (4.56) 23.54 (5.14) 22.68 (5.21) 22.88 (4.83) 0.94
Occupation Housewife 48% 58.3% 70.8% 64% 0.81
Private employee 36% 29.2% 16.7% 24%
Business person 8% 8.3% 8.3% 12%
Government employee 8% 4.2% 4.2% 0%
Approximate sunlight
exposure (min/d)
30 min 76% 83.3% 75% 84% 0.85
>30 to 60 min 12% 12.5% 12.5% 12%
>60 to 90 min 4% 0% 0% 0%
>90 min 8% 4.2% 12.5% 4%
Sunscreen use Used 28% 41.7% 41.7% 44% 0.64
Not used 72% 58.3% 58.3% 56%
Income (US$/mo)* 312 8% 8.3% 12.5% 16% 0.63
>312 to 625 36% 50% 29.2% 44%
>625 to 937 20% 29.2% 33.3% 24%
>937 36% 12.5% 25% 16%
Education status Primary 28% 25% 22.2% 20% 0.21
Secondary 24% 25% 11.2% 40%
College diploma 20% 16.7% 25% 28%
Bachelor's degree 28% 33.3% 41.6% 12%
Skin pigment Light 8% 8.3% 8.3% 16% 0.63
Medium 80% 62.5% 70.8% 56%
Dark 12% 29.2% 20.9% 28%
Cause of menopause Natural 84% 75% 66.7% 80% 0.52
Surgical 16% 25% 33.3% 20%
Data were presented as mean (SD) or percentage, *1 US$ ¼ 32 Thai Bahts.
Fig. 2. Mean serum 25-hydroxy vitamin D levels (ng/mL) among all four groups at baseline, 4 and 12 weeks.
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Table 2
Post hoc analysis of serum 25-hydroxy vitamin D levels at 12 weeks.
Group Group compared p (LSD)
Placebo Vitamin D2 20,000 IU/2 weeks 0.13
Placebo Vitamin D2 20,000 IU/week <0.01
Placebo Vitamin D2 40,000 IU/week <0.01
Vitamin D2 20,000 IU/2
weeks
Vitamin D2 20,000 IU/week 0.02
Vitamin D2 20,000 IU/2
weeks
Vitamin D2 40,000 IU/week <0.01
Vitamin D2 20,000 IU/week Vitamin D2 40,000 IU/week <0.01
LSD: Fisher's Least Significant Difference Test.
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in contrast with a general guideline which recommends
600e800 IU/day (4200e5600 IU/week) of vitamin D for
postmenopausal women. The vitamin D supplementation in
this study of 20,000e40,000 IU/week are equivalent to daily
doses of 2857e5714 IU which are much higher than the
general guideline. This may be due to the difference in the
effectiveness of ergocalciferol (D2) used in this study and
cholecalciferol (D3) recommended in the general guideline
which is still a controversial issue. Several studies [12,13]
suggest that D3 is more potent in raising and maintaining
serum 25-hydroxy vitamin D concentrations and produces a 2-
to 3-fold greater storage of vitamin D than does equimolar D2.
Nevertheless, the only available long interval form of inactive
vitamin D in Thailand is ergocalciferol (D2). And it is
affordable by most of the population as it costs less than
0.04US$ per week for a 20,000 IU tablet. The regimen of
20,000e40,000 IU/week would be cost-effective though
further health economic studies will still be required to
confirm its cost-effectiveness.
The association of seasonal changes and 25-hydroxy
vitamin D levels was reported in one study which showed
no significant differences in the mean total serum 25-hydroxy
vitamin D levels among the vitamin D2 or vitamin D3 sup-
plemented and unsupplemented groups in summer. But in
winter, the mean serum total 25-hydroxy vitamin D levels
were higher in women on vitamin D2 and vitamin D3 sup-
plements compared with unsupplemented women [14]. Since
Thailand is a tropical country, there is no major seasonal
change that will have a significant effect on 25-hydroxy
vitamin D levels. Our study showed that the regimen ofTable 3
Changes in lifestyle after 12 weeks.
Placebo Vitamin D2 20
IU/2 weeks
Exercise Increased 44% 39.1%
No 46% 60.9%
Sunlight exposure Increased 44% 56.5%
No 56% 43.5%
Intake of vitamin D
rich diet
Increased 24% 34.8%
No 76% 65.2%
Data were presented as percentage. Chi-square was used to compare the differencvitamin D2 20,000 IU every 2 weekly may not be enough to
raise serum 25-hydroxy vitamin D level to sufficiency levels.
This implies that it may not be appropriate to prescribe this
regimen to those who are in real need of vitamin D sup-
plementation e.g., postmenopausal women with vitamin D
deficiency. Nevertheless, 16% of participants in the placebo
group were found to achieve sufficiency level after 12 weeks.
This is probably due to the changes in lifestyle due to
increasing health awareness once the group participated in
the study. This was indirectly shown by the increase in
sunlight exposure and increased intake of vitamin D rich
diet.
In this 12 week study, no case of serum 25-hydroxy
vitamin D level >50 ng/mL was seen, though this is not yet
generally agreeable toxic level. Although the International
Osteoporosis Foundation (IOF) has recommended to retest of
serum 25-hydroxy vitamin D level after 3 months of supple-
mentation in high risk individuals [15], a longer than 12 week
study may be needed to confirm the plateau level with pro-
longed use of high dose vitamin D2. Furthermore, it may be
more prudent to have a surveillance of vitamin D toxicity such
as hypercalcaemia and hypercalciuria, for safety reasons since
we did not closely monitor of serum or urinary calcium in this
study. Nevertheless, we did not find any cases with clinical
symptoms of hypercalcaemia during the 12 week study
period.
5. Conclusion
Vitamin D2 (ergocalciferol) supplementation was found to
significantly increase serum 25-hydroxy vitamin D level from
baseline. The once weekly regimen of vitamin D2 40,000 IU
was found to be the most effective, raising the serum 25-
hydroxy vitamin D level sufficiency level in most of the
subjects. The once weekly vitamin D2 20,000 IU may be
another option, although less than half of the participants
achieved sufficiency levels. No case of vitamin D intoxication
(25-hydroxy vitamin D > 50 ng/mL) was observed in this
study.
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